Leukemia News

Hagop Kantarjian, MD, received Society of Hematologic Oncology’s Emil J Freireich Distinguished Pioneer Award.

Results from the American Association for Cancer Research’s annual Cancer Progress Report revealed that the age-adjusted overall cancer death rate in the U.S. fell by 33% between 1991 and 2020.

The FDA announced several regulatory actions the past few weeks.

Early response to ponatinib appeared predictive of survival among certain patients with chronic myeloid leukemia, according to findings presented at Society of Hematologic Oncology Annual Meeting.

Intensive consolidation chemotherapy prior to allogeneic hematopoietic stem cell transplant provided no greater benefit than nonintensive consolidation for older adults with acute myeloid leukemia, according to study results.

Several factors contributed to inequities of outcomes among people with hematologic malignancies in the United States, according to findings presented at Society of Hematologic Oncology Annual Meeting.

Ponatinib improved outcomes compared with imatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, according to study results presented at Society of Hematologic Oncology Annual Meeting.

Pediatric-inspired protocols and hyper-CVAD conferred comparable survival for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia, according to study results.

The FDA approved luspatercept-aamt as first-line treatment for anemia among certain adults with myelodysplastic syndrome.

Hagop Kantarjian, MD, is internationally recognized as a pioneer in the medical field.